CDKN2A and lung carcinoma: A third recent study reported that 9p21.3 loss (as assessed by CDKN2A, CDKN2B plus MTAP) was associated with poor survival after anti-PD-1 monotherapy but not in ICT–chemotherapy combination treated patients with nonsquamous lung cancer (34).